Compare ANPA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | CNTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 47.7M |
| IPO Year | 2024 | 2021 |
| Metric | ANPA | CNTX |
|---|---|---|
| Price | $1.16 | $0.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.14 |
| AVG Volume (30 Days) | 18.1K | ★ 1.2M |
| Earning Date | 09-30-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $0.18 |
| 52 Week High | $180.64 | $3.62 |
| Indicator | ANPA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 35.39 |
| Support Level | N/A | $0.18 |
| Resistance Level | $2.18 | $0.36 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 11.34 | 14.03 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.